ArticleJournal of gastrointestinal cancer2016
Diagnostic and Prognostic Value of miR-1287 in Colorectal Cancer.
Article in Journal of gastrointestinal cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Non-digestible carbohydrates supplementation increases miR-32 expression in the healthy human colorectal epithelium: A randomized controlled trial.Molecular carcinogenesis · 2017Trial
- miR-4796 enhances the sensitivity of breast cancer cells to ionising radiation by impairing the DNA repair pathway.Breast cancer (Tokyo, Japan) · 2023Article
- Serum miR-92a-1 is a novel diagnostic biomarker for colorectal cancer.Journal of cellular and molecular medicine · 2020Article
- CircRNA CDR1as/miR-1287/Raf1 Axis Modulates Hepatocellular Carcinoma Progression Through MEK/ERK Pathway.Cancer management and research · 2020Article
- miR-940 potentially promotes proliferation and metastasis of endometrial carcinoma through regulation of MRVI1.Bioscience reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMicroRNAs are non-coding RNAs that regulate the gene expression at post-transcriptional level. This futuristic study characterized the contribution of miR-1287 to the colorectal cancer (CRC) tumorigenesis.
methodsThe real-time reverse transcription-polymerase chain reaction was used to examine miR-1287 expression levels, prospectively in 40 pairs of CRC tissue samples and adjacent noncancerous tissues (>2 cm from cancer tissue).
resultsNo significant relationship was found between miR-1287 expression levels and clinicopathological features. Showing significant changes overall, MiR-1287 was significantly upregulated in the group of CRC samples compared with matched noncancerous tissue samples. A receiver operating characteristic (ROC) curve also showed ROC area (AROC) of 34 % with 1.0 and 0.02 sensitivity and specificity, respectively. Expression of miR-1287, with a value of 0.34, P value = 1.98, and P > 0.05, revealed that this microRNA has a low sensitivity and specificity to be regarded as a tumor marker.
conclusionsWith regard to recent increased rate of CRC in the world, the present study may be a contribution, though very small, in the diagnosis and consequently in the treatment of CRC patients.
Indexed as
Identifiers
27251300What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.